PRTA – prothena corporation plc - ordinary shares (US:NASDAQ)
Stock Stats
News
Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.
Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.
Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.
Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: Fennell Todd W.
Form SC 13G/A PROTHENA CORP PUBLIC Filed by: SCULLY WILLIAM P
Form 8-K PROTHENA CORP PUBLIC For: Nov 12
Form 10-Q PROTHENA CORP PUBLIC For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.